Michael Patrick Miller Sells 200 Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) EVP Michael Patrick Miller sold 200 shares of the stock in a transaction on Monday, July 17th. The stock was sold at an average price of $154.97, for a total transaction of $30,994.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Michael Patrick Miller also recently made the following trade(s):

  • On Thursday, June 15th, Michael Patrick Miller sold 200 shares of Jazz Pharmaceuticals PLC stock. The stock was sold at an average price of $150.65, for a total transaction of $30,130.00.
  • On Monday, May 15th, Michael Patrick Miller sold 200 shares of Jazz Pharmaceuticals PLC stock. The stock was sold at an average price of $152.98, for a total transaction of $30,596.00.

Shares of Jazz Pharmaceuticals PLC (NASDAQ JAZZ) traded down 0.66% during trading on Friday, hitting $142.71. 476,916 shares of the stock were exchanged. The firm’s 50-day moving average is $154.90 and its 200 day moving average is $146.69. Jazz Pharmaceuticals PLC has a 1-year low of $95.80 and a 1-year high of $163.75. The company has a market cap of $8.57 billion, a P/E ratio of 21.98 and a beta of 1.10.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.85 by $0.13. Jazz Pharmaceuticals PLC had a return on equity of 22.75% and a net margin of 25.69%. The firm had revenue of $394.39 million for the quarter, compared to the consensus estimate of $410.83 million. During the same period in the prior year, the company earned $2.67 EPS. The company’s revenue for the quarter was up 3.5% compared to the same quarter last year. Equities analysts forecast that Jazz Pharmaceuticals PLC will post $10.87 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Michael Patrick Miller Sells 200 Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Stock” was first posted by BNB Daily and is owned by of BNB Daily. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://www.baseball-news-blog.com/2017/08/13/jazz-pharmaceuticals-plc-nasdaqjazz-evp-michael-patrick-miller-sells-200-shares-of-stock-updated-updated-updated.html.

Large investors have recently bought and sold shares of the company. FMR LLC boosted its stake in Jazz Pharmaceuticals PLC by 11.4% in the second quarter. FMR LLC now owns 8,290,410 shares of the specialty pharmaceutical company’s stock valued at $1,289,159,000 after buying an additional 849,348 shares in the last quarter. Vanguard Group Inc. boosted its stake in Jazz Pharmaceuticals PLC by 3.4% in the second quarter. Vanguard Group Inc. now owns 4,677,223 shares of the specialty pharmaceutical company’s stock valued at $727,308,000 after buying an additional 153,908 shares in the last quarter. BlackRock Inc. boosted its stake in Jazz Pharmaceuticals PLC by 3,163.9% in the first quarter. BlackRock Inc. now owns 3,215,159 shares of the specialty pharmaceutical company’s stock valued at $466,615,000 after buying an additional 3,116,652 shares in the last quarter. Janus Capital Management LLC boosted its stake in Jazz Pharmaceuticals PLC by 46.8% in the first quarter. Janus Capital Management LLC now owns 1,470,245 shares of the specialty pharmaceutical company’s stock valued at $213,367,000 after buying an additional 468,940 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in Jazz Pharmaceuticals PLC by 3.2% in the first quarter. Bank of New York Mellon Corp now owns 1,447,760 shares of the specialty pharmaceutical company’s stock valued at $210,114,000 after buying an additional 44,973 shares in the last quarter. 86.43% of the stock is owned by institutional investors and hedge funds.

Several research firms recently issued reports on JAZZ. Piper Jaffray Companies reaffirmed a “buy” rating and set a $177.00 price objective on shares of Jazz Pharmaceuticals PLC in a report on Thursday. Wells Fargo & Company reaffirmed an “outperform” rating and set a $177.00 price objective (down from $178.00) on shares of Jazz Pharmaceuticals PLC in a report on Thursday. Cowen and Company reaffirmed an “outperform” rating and set a $190.00 price objective on shares of Jazz Pharmaceuticals PLC in a report on Wednesday. Deutsche Bank AG set a $175.00 price objective on shares of Jazz Pharmaceuticals PLC and gave the stock a “buy” rating in a report on Wednesday. Finally, Royal Bank Of Canada reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals PLC in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and nineteen have issued a buy rating to the stock. Jazz Pharmaceuticals PLC presently has a consensus rating of “Buy” and an average target price of $182.72.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Insider Buying and Selling by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply